Purple Biotech (PPBT) Income from Non-Controlling Interests (2017 - 2026)
Purple Biotech (PPBT) reported Income from Non-Controlling Interests of $3000.0 for Q1 2026, down 93.75% year-over-year from $48000.0 in Q1 2025, and down 96.91% quarter-over-quarter from $97000.0 in Q4 2025.
Purple Biotech (PPBT) Income from Non-Controlling Interests (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has 10 years of Income from Non-Controlling Interests data on file, last reported at $3000.0 in Q1 2026.
- Income from Non-Controlling Interests for Q1 2026 came in at $3000.0, down 93.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $106000.0 (up 120.83% YoY), and the FY2025 annual result was -$55000.0, down 207.84% from the prior year.
- Income from Non-Controlling Interests fell to $3000.0 in Q1 2026 per PPBT's latest filing, from $97000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $162000.0 in Q1 2023 and troughed at $2000.0 in Q3 2025.
- A 5-year average of $36588.2 and a median of $22000.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2022 and 2025: Income from Non-Controlling Interests sank 95.08% in 2022, then jumped 1840.0% in 2025.
- A 5-year view of Income from Non-Controlling Interests shows it stood at $32000.0 in 2022, then decreased by 3.12% to $31000.0 in 2023, then sank by 83.87% to $5000.0 in 2024, then jumped by 1840.0% to $97000.0 in 2025, then slumped by 96.91% to $3000.0 in 2026.
- Business Quant data shows PPBT's Income from Non-Controlling Interests at $3000.0 in Q1 2026, $97000.0 in Q4 2025, and $2000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Purple Biotech | 261.30 Mn | 254.88 Mn | - | 3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,000.00 |
| Dec 31, 2025 | 97,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 48,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 61,000.00 |
| Mar 31, 2024 | 71,000.00 |
| Dec 31, 2023 | 31,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Jun 30, 2023 | 22,000.00 |
| Mar 31, 2023 | 162,000.00 |
| Dec 31, 2022 | 32,000.00 |
| Sep 30, 2022 | 25,000.00 |
| Jun 30, 2022 | 16,000.00 |
| Mar 31, 2022 | 19,000.00 |
| Dec 31, 2021 | 34,000.00 |
| Sep 30, 2021 | 313,000.00 |
| Jun 30, 2021 | 325,000.00 |